NCT01260922

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

A Relative Bioavailability Study of 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Teva Pharmaceuticals USA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study investigated the relative bioavailability (rate and extent of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally disintegrating tablet) in healthy adult subjects administered under fasting conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Donepezil Hydrochloride	10 mg Orally Disintegrating Tablet
DRUG	Aricept®	10 mg Orally Disintegrating Tablet

Timeline

• Start date: 2006-04-01
• Primary completion: 2006-05-01
• Completion: 2006-05-01
• First posted: 2010-12-15
• Last updated: 2011-02-21
• Results posted: 2011-02-21

Locations

1 site across 1 country: United States